Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Deals Drop In 2015, With IVD-Sector Transactions Still Leading The Pack

This article was originally published in The Gray Sheet

Executive Summary

There were 225 medtech M&A deals in 2015, down from 269 in 2014, according to Clinica's M&A Tracker. The in vitro diagnostics sector continues to be the most popular for transactions.

You may also be interested in...



Finding The Fit For Ophthalmology In The New Pfizer

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.

More Than Just A VAD Maker: HeartWare Broadens Heart Failure Focus With Valtech Buy

The deal will make HeartWare more of a go-to firm for heart-failure specialists, executives say. It comes soon after St. Jude Medical announced its acquisition of Thoratec, another VAD-focused firm whose technology will now be sold alongside a broader set of tools for heart-failure caregivers.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT034759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel